Atria Investments Inc Invests $259,000 in Transcat, Inc. $TRNS

Atria Investments Inc acquired a new stake in shares of Transcat, Inc. (NASDAQ:TRNS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,012 shares of the scientific and technical instruments company’s stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of TRNS. Quantbot Technologies LP bought a new position in Transcat in the first quarter valued at about $76,000. State of Wyoming acquired a new position in shares of Transcat in the first quarter valued at approximately $95,000. Morgan Dempsey Capital Management LLC increased its stake in shares of Transcat by 41.7% in the second quarter. Morgan Dempsey Capital Management LLC now owns 1,352 shares of the scientific and technical instruments company’s stock valued at $116,000 after buying an additional 398 shares during the period. US Bancorp DE raised its holdings in Transcat by 14.6% in the 1st quarter. US Bancorp DE now owns 1,770 shares of the scientific and technical instruments company’s stock valued at $132,000 after buying an additional 226 shares during the last quarter. Finally, Hardy Reed LLC acquired a new stake in Transcat during the 2nd quarter worth approximately $217,000. Institutional investors own 98.34% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TRNS. Northland Securities set a $95.00 price target on shares of Transcat in a research report on Thursday, October 23rd. Zacks Research upgraded Transcat from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 7th. Weiss Ratings downgraded Transcat from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. Northland Capmk upgraded Transcat from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $116.00 price target on shares of Transcat in a research note on Friday, August 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Transcat Trading Down 1.7%

Shares of TRNS stock opened at $55.64 on Thursday. Transcat, Inc. has a fifty-two week low of $54.10 and a fifty-two week high of $112.22. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.36 and a current ratio of 2.92. The stock has a 50 day simple moving average of $71.38 and a two-hundred day simple moving average of $78.82. The company has a market cap of $519.01 million, a P/E ratio of 38.91 and a beta of 0.71.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Monday, November 3rd. The scientific and technical instruments company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.02). Transcat had a return on equity of 6.66% and a net margin of 4.64%.The company had revenue of $82.27 million for the quarter, compared to analyst estimates of $79.51 million. Research analysts forecast that Transcat, Inc. will post 2.3 earnings per share for the current year.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.